{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:22:28Z","timestamp":1777983748676,"version":"3.51.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The year 2020 witnessed a heavy death toll due to COVID-19, calling for a global emergency. The continuous ongoing research and clinical trials paved the way for vaccines. But, the vaccine efficacy in the long run is still questionable due to the mutating coronavirus, which makes drug re-positioning a reasonable alternative. COVID-19 has hence fast-paced drug re-positioning for the treatment of COVID-19 and its symptoms. This work builds computational models using matrix completion techniques to predict drug-virus association for drug re-positioning. The aim is to assist clinicians with a tool for selecting prospective antiviral treatments. Since the virus is known to mutate fast, the tool is likely to help clinicians in selecting the right set of antivirals for the mutated isolate. The main contribution of this work is a manually curated database publicly shared, comprising of existing associations between viruses and their corresponding antivirals. The database gathers similarity information using the chemical structure of drugs and the genomic structure of viruses. Along with this database, we make available a set of state-of-the-art computational drug re-positioning tools based on matrix completion. The tools are first analysed on a standard set of experimental protocols for drug target interactions. The best performing ones are applied for the task of re-positioning antivirals for COVID-19. These tools select six drugs out of which four are currently under various stages of trial, namely Remdesivir (as a cure), Ribavarin (in combination with others for cure), Umifenovir (as a prophylactic and cure) and Sofosbuvir (as a cure). Another unanimous prediction is Tenofovir alafenamide, which is a novel Tenofovir prodrug developed in order to improve renal safety when compared to its original counterpart (older version) Tenofovir disoproxil. Both are under trail, the former as a cure and the latter as a prophylactic. These results establish that the computational methods are in sync with the state-of-practice. We also demonstrate how the drugs to be used against the virus would vary as SARS-Cov-2 mutates over time by predicting the drugs for the mutated strains, suggesting the importance of such a tool in drug prediction. We believe this work would open up possibilities for applying machine learning models to clinical research for drug-virus association prediction and other similar biological problems.<\/jats:p>","DOI":"10.1038\/s41598-021-88153-3","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T06:13:30Z","timestamp":1619504010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials"],"prefix":"10.1038","volume":"11","author":[{"given":"Aanchal","family":"Mongia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay Kr.","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Chouzenoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angshul","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"key":"88153_CR1","unstructured":"Coronavirus Update (Live)-Worldometer, 2019. https:\/\/www.worldometers.info\/coronavirus\/. (Accessed 22 June 2020)."},{"issue":"4","key":"88153_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","volume":"38","author":"C Harrison","year":"2020","unstructured":"Harrison, C. Coronavirus puts drug repurposing on the fast track. Nat. Biotechnol. 38(4), 379\u2013381 (2020).","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"88153_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3(8), 673 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"282","key":"88153_CR4","doi-asserted-by":"publisher","first-page":"282ra49","DOI":"10.1126\/scitranslmed.3010286","volume":"7","author":"S He","year":"2015","unstructured":"He, S. et al. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis c virus infection. Sci. Transl. Med. 7(282), 282ra49 (2015).","journal-title":"Sci. Transl. Med."},{"key":"88153_CR5","doi-asserted-by":"crossref","unstructured":"Frantz, S. Drug discovery: Playing dirty (2005).","DOI":"10.1038\/437942a"},{"issue":"12","key":"88153_CR6","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-05-0070","volume":"4","author":"SR McLean","year":"2005","unstructured":"McLean, S. R. et al. Imatinib binding and ckit inhibition is abrogated by the ckit kinase domain i missense mutation val654ala. Mol. Cancer Ther. 4(12), 2008\u20132015 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"88153_CR7","doi-asserted-by":"crossref","unstructured":"Ezzat, A. et al. Computational prediction of drug\u2013target interactions using chemogenomic approaches: an empirical survey. Brief.\nbioinf. 20(4), 1337\u20131357 (2019).","DOI":"10.1093\/bib\/bby002"},{"issue":"3","key":"88153_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.15406\/ppij.2020.08.00292","volume":"8","author":"MA Beg","year":"2020","unstructured":"Beg, M. A. & Athar, F. Anti-HIV and anti-HCV drugs are the putative inhibitors of RNA-dependent-RNA polymerase activity of nsp12 of the sars cov-2 (COVID-19). Pharm. Pharmacol. Int. J. 8(3), 163\u2013172 (2020).","journal-title":"Pharm. Pharmacol. Int. J."},{"key":"88153_CR9","doi-asserted-by":"crossref","unstructured":"Lee, V.S., Chong, W.L., Sukumaran, S.D., Nimmanpipug, P., Letchumanan, V., Goh, B.H., Lee, L.-H., Zain, S.M., & Rahman, N.A. Computational screening and identifying binding interaction of anti-viral and anti-malarial drugs: Toward the potential cure for sars-cov-2. Progress Drug Discov. Biomed. Sci. 3(1) (2020).","DOI":"10.36877\/pddbs.a0000065"},{"issue":"12","key":"88153_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1473-3099(20)30372-8","volume":"20","author":"M Lipsitch","year":"2020","unstructured":"Lipsitch, M., Perlman, S. & Waldor, M. K. Testing COVID-19 therapies to prevent progression of mild disease. Lancet Infect. Diseases 20(12), 1367 (2020).","journal-title":"Lancet Infect. Diseases"},{"key":"88153_CR11","unstructured":"Sahoo, S.K. & Vardhan, S. Computational evidence on repurposing the anti-inuenza drugs baloxavir acid and baloxavir marboxil against COVID-19. arXiv preprint arXiv:2009.01094  (2020)."},{"key":"88153_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fgene.2019.00009","volume":"10","author":"A Mongia","year":"2019","unstructured":"Mongia, A., Sengupta, D. & Majumdar, A. Mcimpute: Matrix completion based imputation for single cell RNA-seq data. Front. Genet. 10, 9 (2019).","journal-title":"Front. Genet."},{"key":"88153_CR13","doi-asserted-by":"crossref","unstructured":"Mongia, A. & Majumdar, A. Deep matrix completion on graphs: Application in drug target interaction prediction. In Proceedings of the IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP 2020), 1324\u20131328. (IEEE, 2020).","DOI":"10.1109\/ICASSP40776.2020.9053827"},{"issue":"3","key":"88153_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1109\/TCBB.2016.2530062","volume":"14","author":"A Ezzat","year":"2017","unstructured":"Ezzat, A., Zhao, P., Min, Wu., Li, X.-L. & Kwoh, C.-K. Drug-target interaction prediction with graph regularized matrix factorization. IEEE\/ACM Trans. Comput. Biol. Bioinform. (TCBB) 14(3), 646\u2013656 (2017).","journal-title":"IEEE\/ACM Trans. Comput. Biol. Bioinform. (TCBB)"},{"issue":"1","key":"88153_CR15","doi-asserted-by":"publisher","first-page":"e0226484","DOI":"10.1371\/journal.pone.0226484","volume":"15","author":"A Mongia","year":"2020","unstructured":"Mongia, A. & Majumdar, A. Drug-target interaction prediction using multi graph regularized nuclear norm minimization. PLoS ONE 15(1), e0226484 (2020).","journal-title":"PLoS ONE"},{"key":"88153_CR16","doi-asserted-by":"crossref","unstructured":"Mongia, A., Chouzenoux, E., & Majumdar, A. Computational prediction of drug-disease association based on graph-regularized one bit matrix completion. bioRxiv (2020). https:\/\/www.biorxiv.org\/content\/10.1101\/2020.04.02.020891v1.abstract.","DOI":"10.1101\/2020.04.02.020891"},{"issue":"5","key":"88153_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","volume":"15","author":"A Zumla","year":"2016","unstructured":"Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C. & Yuen, K.-Y. Coronaviruses|drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15(5), 327\u2013347 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"88153_CR18","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1016\/j.eswa.2008.05.027","volume":"36","author":"J Burez","year":"2009","unstructured":"Burez, J. & Van den Poel, D. Handling class imbalance in customer churn prediction. Expert Syst. Appl. 36(3), 4626\u20134636 (2009).","journal-title":"Expert Syst. Appl."},{"issue":"1","key":"88153_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/nar\/gkw1002","volume":"45","author":"NA Ahlgren","year":"2017","unstructured":"Ahlgren, N. A., Ren, J., Lu, Y. Y., Fuhrman, J. A. & Sun, F. Alignment-free oligonucleotide frequency dissimilarity measure improves prediction of hosts from metagenomically-derived viral sequences. Nucleic Acids Res. 45(1), 39\u201353 (2017).","journal-title":"Nucleic Acids Res."},{"key":"88153_CR20","doi-asserted-by":"crossref","unstructured":"Beigel, J. H., et al. Remdesivir for the treatment of Covid-19. N Engl J Med 383(19), 1813-1826 (2020).","DOI":"10.1056\/NEJMc2022236"},{"issue":"10238","key":"88153_CR21","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","volume":"395","author":"IF-N Hung","year":"2020","unstructured":"Hung, I.F.-N. et al. Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial. Lancet 395(10238), 1695\u20131704 (2020).","journal-title":"Lancet"},{"issue":"9","key":"88153_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1097\/CM9.0000000000000790","volume":"133","author":"Y-M Zeng","year":"2020","unstructured":"Zeng, Y.-M. et al. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir\/ritonavir plus interferon-alpha, and ribavirin plus lopinavir\/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: Study protocol. Chin. Med. J. 133(9), 1132\u20131134 (2020).","journal-title":"Chin. Med. J."},{"key":"88153_CR23","doi-asserted-by":"crossref","unstructured":"Rodrigo, J. et al. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Sci. rep. 10(1), 1\u20135 (2020).","DOI":"10.1038\/s41598-020-66440-9"},{"issue":"1","key":"88153_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5582\/bst.2020.01030","volume":"14","author":"Z Wang","year":"2020","unstructured":"Wang, Z., Chen, X., Yunfei, Lu., Chen, F. & Zhang, W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined chinese and western medicine treatment. Biosci. Trends 14(1), 64\u201368 (2020).","journal-title":"Biosci. Trends"},{"key":"88153_CR25","doi-asserted-by":"crossref","unstructured":"Duan, Y., Hai-Liang, Z., & Chongchen, Z. Advance of promising targets and agents against COVID-19 in China. Drug discovery today 25(5), 810\u2013812 (2020).","DOI":"10.1016\/j.drudis.2020.02.011"},{"key":"88153_CR26","unstructured":"New trial starts in UK to see if ibuprofen can help prevent severe breathing problems in Covid-19 patients. https:\/\/www.thejournal.ie\/ibuprofen-trial-coronavirus-5113390-Jun2020\/."},{"key":"88153_CR27","doi-asserted-by":"crossref","unstructured":"Martins\u2010Filho, Paulo Ricardo, Edmundo Marques do Nascimento\u2010J\u00fanior, and Victor Santana Santos. No current evidence supporting risk of using Ibuprofen in patients with COVID\u201019. Int J Clin Pract 74(10), e13576 (2020).","DOI":"10.1111\/ijcp.13576"},{"key":"88153_CR28","doi-asserted-by":"crossref","unstructured":"Chatterjee, S. An overview of mutations occurring within the coronavirus-2 genome: Mutations data reporting on sars-cov-2. SSRN 3632241 (2020).","DOI":"10.2139\/ssrn.3632241"},{"key":"88153_CR29","doi-asserted-by":"crossref","unstructured":"Lou, Yan, et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci 157, 105631 (2021).","DOI":"10.1016\/j.ejps.2020.105631"},{"issue":"11","key":"88153_CR30","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/jac\/dkaa332","volume":"75","author":"HA Kasgari","year":"2020","unstructured":"Kasgari, H. A. et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: A single-centre, randomized controlled trial. J. Antimicrobial Chemother. 75(11), 3373\u20133378 (2020).","journal-title":"J. Antimicrobial Chemother."},{"key":"88153_CR31","doi-asserted-by":"crossref","unstructured":"Elalfy, H., Besheer, T., El-Mesery, A., El-Gilany, A.H., Elazez, M.S.A., Alhawarey, A., Alegezy, M., Elhadidy, T., Hewidy, A.A., Zaghloul, H., et al. Effect of a combination of nitazoxanide, ribavirin and ivermectin plus zinc supplement (mans. nriz study) on the clearance of mild COVID-19. J. Med. Virol. (2021).","DOI":"10.1002\/jmv.26880"},{"issue":"11","key":"88153_CR32","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1093\/jac\/dkaa331","volume":"75","author":"G Eslami","year":"2020","unstructured":"Eslami, G. et al. The impact of sofosbuvir\/daclatasvir or ribavirin in patients with severe COVID-19. J. Antimicrob. Chemother. 75(11), 3366\u20133372 (2020).","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"88153_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-66440-9","volume":"10","author":"R J\u00e1come","year":"2020","unstructured":"J\u00e1come, R., Campillo-Balderas, J. A., de Le\u00f3n, S. P., Becerra, A. & Lazcano, A. Sofosbuvir as a potential alternative to treat the sars-cov-2 epidemic. Sci. Rep. 10(1), 1\u20135 (2020).","journal-title":"Sci. Rep."},{"issue":"3","key":"88153_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/jac\/dkaa501","volume":"76","author":"F Roozbeh","year":"2021","unstructured":"Roozbeh, F. et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: A double-blind, randomized controlled trial. J. Antimicrob. Chemother. 76(3), 753\u2013757 (2021).","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"88153_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.arcmed.2020.04.018","volume":"51","author":"B Sayad","year":"2020","unstructured":"Sayad, B., Sobhani, M. & Khodarahmi, R. Sofosbuvir as repurposed antiviral drug against COVID-19: Why were we convinced to evaluate the drug in a registered\/approved clinical trial?. Arch. Med. Res. 51(6), 577\u2013581 (2020).","journal-title":"Arch. Med. Res."},{"key":"88153_CR36","unstructured":"Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334928."},{"issue":"8","key":"88153_CR37","first-page":"1552","volume":"31","author":"GC Clososki","year":"2020","unstructured":"Clososki, G. C. et al. Tenofovir disoproxil fumarate: New chemical developments and encouraging in vitro biological results for sars-cov-2. J. Braz. Chem. Soc. 31(8), 1552\u20131556 (2020).","journal-title":"J. Braz. Chem. Soc."},{"key":"88153_CR38","doi-asserted-by":"crossref","unstructured":"Kutlu, O. Can tenofovir diphosphate be a candidate drug for sars-cov2? First clinical perspective. Int. J. Clin. Practice e13792 (2021).","DOI":"10.22541\/au.160157573.37572063"},{"issue":"19","key":"88153_CR39","doi-asserted-by":"publisher","first-page":"9733","DOI":"10.1128\/JVI.00694-10","volume":"84","author":"R Sanju\u00e1n","year":"2010","unstructured":"Sanju\u00e1n, R., Nebot, M. R., Chirico, N., Mansky, L. M. & Belshaw, R. Viral mutation rates. J. Virol. 84(19), 9733\u20139748 (2010).","journal-title":"J. Virol."},{"key":"88153_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02344-6","volume":"18","author":"M Pachetti","year":"2020","unstructured":"Pachetti, M. et al. Emerging sars-cov-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J. Transl. Med. 18, 1\u20139 (2020).","journal-title":"J. Transl. Med."},{"key":"88153_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/IDR.S105473","volume":"10","author":"M Hussain","year":"2017","unstructured":"Hussain, M., Galvin, H. D., Haw, T. Y., Nutsford, A. N. & Husain, M. Drug resistance in inuenza a virus: The epidemiology and management. Infect. Drug Resistance 10, 121 (2017).","journal-title":"Infect. Drug Resistance"},{"issue":"Supplement 4","key":"88153_CR42","doi-asserted-by":"publisher","first-page":"S750","DOI":"10.1093\/clinids\/11.Supplement_4.S750","volume":"11","author":"JW Huggins","year":"1989","unstructured":"Huggins, J. W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Diseases 11(Supplement 4), S750\u2013S761 (1989).","journal-title":"Rev. Infect. Diseases"},{"issue":"6","key":"88153_CR43","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2012.02.015","volume":"142","author":"EAK Schaefer","year":"2012","unstructured":"Schaefer, E. A. K. & Chung, R. T. Anti-hepatitis c virus drugs in development. Gastroenterology 142(6), 1340\u20131350 (2012).","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"88153_CR44","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart, D. S. et al. Drugbank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34(suppl 1), D668\u2013D672 (2006).","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"88153_CR45","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/art.38221","volume":"66","author":"A Chopra","year":"2014","unstructured":"Chopra, A., Saluja, M. & Venugopalan, A. Effectiveness of chloroquine and inammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection. Arthritis Rhumatol. 66(2), 319\u2013326 (2014).","journal-title":"Arthritis Rhumatol."},{"issue":"6","key":"88153_CR46","doi-asserted-by":"publisher","first-page":"e100531","DOI":"10.1371\/journal.pone.0100531","volume":"9","author":"I Das","year":"2014","unstructured":"Das, I. et al. Heat shock protein 90 positively regulates chikungunya virus replication by stabilizing viral non-structural protein nsp2 during infection. PLoS ONE 9(6), e100531 (2014).","journal-title":"PLoS ONE"},{"issue":"3","key":"88153_CR47","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq, E. & Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29(3), 695\u2013747 (2016).","journal-title":"Clin. Microbiol. Rev."},{"key":"88153_CR48","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/infdis\/jiw358","volume":"8","author":"KM Gallegos","year":"2016","unstructured":"Gallegos, K. M., Drusano, G. L., Argenio, D. Z. D. & Brown, A. N. Chikungunya virus: In vitro response to combination therapy with ribavirin and interferon alfa 2a. J. Infect. Diseases 8, 1192\u20131197 (2016).","journal-title":"J. Infect. Diseases"},{"key":"88153_CR49","unstructured":"Jin, Z., Zhao, Y., Sun, Y., Zhang, B., Wang, H., Wu, Y., Zhu, Y., Zhu, C., Hu, T., Du, X. et al. Structural basis for the inhibition of COVID-19 virus main protease by carmofur, an antineoplastic drug. bioRxiv (2020). https:\/\/www.biorxiv.org\/content\/10.1101\/2020.04.09.033233v1. (abstract)."},{"key":"88153_CR50","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.4065\/mcp.2011.0309","volume":"86","author":"RR Razonable","year":"2011","unstructured":"Razonable, R. R. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin. Proc. 86, 1009\u20131026 (2011) (Elsevier).","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"88153_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-15467-6","volume":"7","author":"SA Shiryaev","year":"2017","unstructured":"Shiryaev, S. A. et al. Repurposing of the anti-malaria drug chloroquine for zika virus treatment and prophylaxis. Sci. Rep. 7(1), 1\u20139 (2017).","journal-title":"Sci. Rep."},{"issue":"6","key":"88153_CR52","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1128\/AAC.01755-09","volume":"54","author":"N Sugaya","year":"2010","unstructured":"Sugaya, N. & Ohashi, Y. Long-acting neuraminidase inhibitor laninamivir octanoate (cs-8958) versus oseltamivir as treatment for children with inuenza virus infection. Antimicrob. Agents Chemother. 54(6), 2575\u20132582 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"88153_CR53","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1163\/156856003322699627","volume":"11","author":"B Winther","year":"2003","unstructured":"Winther, B. & Mygind, N. Potential benefits of ibuprofen in the treatment of viral respiratory infections. Inammopharmacology 11(4), 445 (2003).","journal-title":"Inammopharmacology"},{"issue":"D1","key":"88153_CR54","doi-asserted-by":"publisher","first-page":"D593","DOI":"10.1093\/nar\/gkr859","volume":"40","author":"BE Pickett","year":"2012","unstructured":"Pickett, B. E. et al. Vipr: An open bioinformatics database and analysis resource for virology research. Nucleic Acids Res. 40(D1), D593\u2013D598 (2012).","journal-title":"Nucleic Acids Res."},{"issue":"suppl 1","key":"88153_CR55","doi-asserted-by":"publisher","first-page":"D354","DOI":"10.1093\/nar\/gkj102","volume":"34","author":"M Kanehisa","year":"2006","unstructured":"Kanehisa, M. et al. From genomics to chemical genomics: New developments in KEGG. Nucleic Acids Res. 34(suppl 1), D354\u2013D357 (2006).","journal-title":"Nucleic Acids Res."},{"key":"88153_CR56","unstructured":"NCBI. https:\/\/www.ncbi.nlm.nih.gov\/."},{"issue":"suppl 2","key":"88153_CR57","doi-asserted-by":"publisher","first-page":"W652","DOI":"10.1093\/nar\/gkq367","volume":"38","author":"M Hattori","year":"2010","unstructured":"Hattori, M., Tanaka, N., Kanehisa, M. & Goto, S. Simcomp\/subcomp: Chemical structure search servers for network analyses. Nucleic Acids Res. 38(suppl 2), W652\u2013W656 (2010).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"88153_CR58","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1137\/11085997X","volume":"6","author":"E Chouzenoux","year":"2013","unstructured":"Chouzenoux, E., Jezierska, A., Pesquet, J. C. & Talbot, H. A majorize-minimize subspace approach for l2\u2013l0 image regularization. SIAM J. Imaging Sci. 6(1), 563\u2013591 (2013).","journal-title":"SIAM J. Imaging Sci."},{"issue":"3","key":"88153_CR59","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1109\/TSP.2016.2601299","volume":"65","author":"Y Sun","year":"2017","unstructured":"Sun, Y., Babu, P. & Palomar, D. P. Majorization-minimization algorithms in signal processing, communications, and machine learning. IEEE Trans. Signal Process. 65(3), 794\u2013816 (2017).","journal-title":"IEEE Trans. Signal Process."},{"issue":"1","key":"88153_CR60","first-page":"3367","volume":"16","author":"T Hastie","year":"2015","unstructured":"Hastie, T., Mazumder, R., Lee, J. D. & Zadeh, R. Matrix completion and low-rank SVD via fast alternating least squares. J. Mach. Learn. Res. 16(1), 3367\u20133402 (2015).","journal-title":"J. Mach. Learn. Res."},{"key":"88153_CR61","doi-asserted-by":"publisher","first-page":"10096","DOI":"10.1109\/ACCESS.2016.2611583","volume":"4","author":"S Tariyal","year":"2016","unstructured":"Tariyal, S., Majumdar, A., Singh, R. & Vatsa, M. Deep dictionary learning. IEEE Access 4, 10096\u201310109 (2016).","journal-title":"IEEE Access"},{"key":"88153_CR62","doi-asserted-by":"crossref","unstructured":"Mongia, A., Debarka, S. & Angshul, M. deepmc: Deep matrix completion for imputation of single-cell rna-seq\ndata. J. Comput. Biol. 27(7), 1011\u20131019 (2020).","DOI":"10.1089\/cmb.2019.0278"},{"key":"88153_CR63","unstructured":"Chung, Fan RK, and Fan Chung Graham. Spectral graph theory. No. 92. American Math. Soc., 1997."},{"issue":"6","key":"88153_CR64","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10208-009-9045-5","volume":"9","author":"EJ Candes","year":"2009","unstructured":"Candes, E. J. & Recht, B. Exact matrix completion via convex optimization. Found. Comput. Math. 9(6), 717\u2013772 (2009).","journal-title":"Found. Comput. Math."},{"issue":"5","key":"88153_CR65","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1109\/TIT.2010.2044061","volume":"56","author":"EJ Cand\u00e8s","year":"2010","unstructured":"Cand\u00e8s, E. J. & Tao, T. The power of convex relaxation: Near-optimal matrix completion. IEEE Trans. Inf. Theor. 56(5), 2053\u20132080 (2010).","journal-title":"IEEE Trans. Inf. Theor."},{"key":"88153_CR66","doi-asserted-by":"crossref","unstructured":"Boyd, S., Parikh, N., Chu, E., Peleato, B., Eckstein, J. Distributed optimization and statistical learning via the alternating direction method of multipliers. Found. Trends Mach. Learn. 3(1), (2010).","DOI":"10.1561\/9781601984616"},{"issue":"6","key":"88153_CR67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1109\/MSP.2014.2377273","volume":"32","author":"N Komodakis","year":"2015","unstructured":"Komodakis, N. & Pesquet, J. Playing with duality: An overview of recent primal-dual approaches for solving large-scale optimization problems. IEEE Signal Process. Mag. 32(6), 31\u201354 (2015).","journal-title":"IEEE Signal Process. Mag."},{"issue":"9","key":"88153_CR68","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1109\/TIP.2011.2128335","volume":"20","author":"N Pustelnik","year":"2011","unstructured":"Pustelnik, N., Chaux, C. & Pesquet, J.-C. Parallel proximal algorithm for image restoration using hybrid regularization. IEEE Trans. Image Process. 20(9), 2450\u20132462 (2011).","journal-title":"IEEE Trans. Image Process."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88153-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88153-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88153-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T21:29:51Z","timestamp":1675200591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88153-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88153"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88153-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.36227\/techrxiv.12609422","asserted-by":"object"},{"id-type":"doi","id":"10.36227\/techrxiv.12609422.v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]},"assertion":[{"value":"3 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9047"}}